No Data
Is Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Trading At A 39% Discount?
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Zejing Pharmaceutical: Zejing Pharmaceutical 2024 Annual Performance Report Announcement
Zejing Pharmaceutical 2024 Annual Results Report Announcement
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) CEO Zelin Sheng Is the Most Upbeat Insider, and Their Holdings Increased by 9.5% Last Week
Suzhou Zelgen BiopharmaceuticalsLtd's (SHSE:688266) Investors Will Be Pleased With Their Favorable 53% Return Over the Last Year
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Popularity With Investors Under Threat As Stock Sinks 29%
